POP Biotechnologies

POP Biotechnologies, Inc. is a Buffalo-based biotechnology company that develops nanoparticle-based vaccines and therapeutics using its proprietary porphyrin-phospholipid (PoP) liposome technology. Its core platform, Spontaneous Nanoliposome Antigen Particleization (SNAP), is a plug-and-play system that allows for the rapid, stable display of protein and peptide antigens on liposomes. By leveraging a cobalt-modified variant of this technology, known as CoPoP, the company can streamline protein purification and enhance immune responses, making it well-suited for the rapid development of vaccines against emerging pathogens and cancer immunotherapies.

The company's technology has been clinically validated, most notably through the Phase 3 clinical trials of the EuCorVac-19 COVID-19 vaccine. POP Biotechnologies partners with academic and industry collaborators to advance its pipeline, which includes candidates for infectious diseases such as influenza, RSV, and Shingles, as well as immunotherapy applications for oncology and Alzheimer’s disease. Supported by federal grants and collaborations with organizations like CEPI, the company aims to improve vaccine manufacturing efficiency and vaccine accessibility, providing versatile solutions that can be quickly adapted for pandemic preparedness and targeted treatment needs.